Figure S2 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S2: IAP antagonist treatment skewsT-cell development toward the CD8 lineage in fetal thymic organ culture (FTOC).</p

Figure S1 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S1: Structure of IAP antagonists</p

Figure S3 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S3: IAP antagonism alone does not induce apoptosis of iNKT cells or conventional T cells.</p

Figure S4 from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

S4: CD1d knockout mice show a significant contribution of the costimulatory effects of LBW-242 on cytokine production by CD4+ T cells.</p

Supplemental Figure Legends from IAP Antagonists Enhance Cytokine Production from Mouse and Human iNKT Cells

Figure legends</p

Data_Sheet_1_Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer.PDF

Radiation therapy induces immunogenic cell death, which can theoretically stimulate T cell priming and induction of tumor-specific memory T cell responses, serving as an in situ vaccine. In practice, this abscopal effect is rarely observed. We use two mouse models of pancreatic cancer to show that a single dose of stereotactic body radiation therapy (SBRT) synergizes with intratumoral injection of agonistic anti-CD40, resulting in regression of non-treated contralateral tumors and formation of long-term immunologic memory. Long-term survival was not observed when mice received multiple fractions of SBRT, or when TGFβ blockade was combined with SBRT. SBRT and anti-CD40 was so effective at augmenting T cell priming, that memory CD8 T cell responses to both tumor and self-antigens were induced, resulting in vitiligo in long-term survivors.</p

Supplemental Data from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8⁺ T Cell–Effector Responses

Supplemental Table and Figures S1 and S2</p

Supplemental Methods from Altered Binding of Tumor Antigenic Peptides to MHC Class I Affects CD8⁺ T Cell–Effector Responses

Supplemental Methods</p

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHH

Supplementary Figure S1 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S1. B3 binds to PD-L1 on multiple tumor types.</p